QTTB (Q32 Bio) Dividend Yield % : 0.00% (As of Dec. 15, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Dividend Yield %?

As of today (2024-12-15), the Trailing Annual Dividend Yield of Q32 Bio is 0.00%.

The historical rank and industry rank for Q32 Bio's Dividend Yield % or its related term are showing as below:

QTTB's Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.39
* Ranked among companies with meaningful Dividend Yield % only.

Q32 Bio's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00.

As of today (2024-12-15), the Forward Dividend Yield % of Q32 Bio is 0.00%.

Q32 Bio's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Q32 Bio Dividend Yield % Historical Data

The historical data trend for Q32 Bio's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Dividend Yield % Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Dividend Yield %

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Dividend Yield %	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Q32 Bio's Dividend Yield %

For the Biotechnology subindustry, Q32 Bio's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Dividend Yield % falls into.

Q32 Bio Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Q32 Bio (NAS:QTTB) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Q32 Bio Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Dividend Yield %

Comparable Companies

Traded in Other Exchanges

DB0:Germany

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.